Importation To Address Drug Pricing? Just Do It – But Don’t Justify It
The idea of permitting importation of competitors to products like Daraprim has an undeniable appeal, and – unlike essentially every other idea on the table to deal with drug pricing – would actually address the singular example that helped kick off the current debate. But creating a legal framework to justify the action is very perilous for the industry overall.
You may also be interested in...
Show Us The Birth Certificate? An Authorless US FDA Import Policy
For two decades it has been almost dogma in the US pharmaceutical industry that no FDA commissioner would sign off on a policy to permit wholesale imports of drugs from Canada. Now that a proposed rule has been issued – it still may be true.
Who's Promised What: A Guide To Pharma Drug Pricing Pledges
Have pharma companies responded sufficiently to President Trump's call for “massive” price reductions?
Drug Importation Can Be Triggered By 'Excessive' Price Increases; Now US FDA Has To Decide What That Means
Did FDA Commissioner Scott Gottlieb and HHS Secretary Alex Azar have a change of heart on importation? Or are they being pressured from above?